A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
require the label of a drug that is intended for human 
use and contains an ingredient that is derived directly 
or indirectly from a gluten-containing grain to identify 
each such ingredient, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Gluten in Medicine 
4
Disclosure Act of 2021’’. 
5
00:12 May 28, 2021
H2435
2 
•HR 2435 IH
SEC. 2. LABELING OF DRUGS WITH AN INGREDIENT MADE 
1
FROM A GLUTEN-CONTAINING GRAIN. 
2
(a) MISBRANDING.—Section 502 of the Federal 
3
Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amend-
4
ed by adding at the end the following: 
5
‘‘(gg) If it is a drug— 
6
‘‘(1) that is intended for human use; 
7
‘‘(2) that contains an ingredient that is derived 
8
directly or indirectly from a gluten-containing grain 
9
(including wheat, barley, rye, and their crossbred hy-
10
brids); and 
11
‘‘(3) whose label fails— 
12
‘‘(A) to state that the drug contains such 
13
an ingredient; and 
14
‘‘(B) to identify each such ingredient and 
15
the type of gluten-containing grain from which 
16
it is derived.’’. 
17
(b) APPLICABILITY.—Section 502(gg) of the Federal 
18
Food, Drug, and Cosmetic Act, as added by subsection 
19
(a) of this section, shall apply beginning on the sooner 
20
of— 
21
(1) a date to be determined by the Secretary of 
22
Health and Human Services; and 
23
(2) the date that is 2 years after the date of the 
24
enactment of this Act. 
25
Æ 
00:12 May 28, 2021
H2435
